968P - Cytokeratin 4 is a novel predictive marker in early stage (T1/2) oral tongue squamous cell carcinoma (TSCC)

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Presenter Tomohiro Enokida
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors T. Enokida1, S. Fujii2, M. Takahashi3, T. Wakasugi1, T. Yamazaki1, S. Okano1, R. Hayashi4, M. Tahara1
  • 1Department Of Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2Division Of Pathology, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 277-8577 - Kashiwa/JP
  • 3Department Of Digestive Endoscopy, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 4Head And Neck Surgery Division, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP



We have already shown that cytokeratin 4 (CK4) protein expression is a favorable prognostic factor for the patients with locally advanced TSCC. The aim of this study is to identify predictive markers of TSCC recurrence and cancer specific death among clinicopathological factors including CK4 protein expression.


Two cohorts including discovery (79 cases) and validation (94 cases) cohorts consisting of the patients with primary TSCC were evaluated. Eligibility criteria were as follows: 1) preoperative imaging diagnosis of cT1/2N0; 2) primary partial glossectomy without lymph node dissection; and 3) TSCCs with pT1/2. The relationship between clinicopathological factors and relapse-free survival (RFS) and cancer specific survival (CSS) was statistically analyzed.


Median age, pT, median tumor thickness and rate of positive immunohisthochemical staining for CK4 in tumor cells in discovery cohort were 63 years (26-89), pT1/2 = 47%/53%, 6 mm (0.75-16), and 59%, respectively. 3-year RFS and 3-year CSS rates were 70.3% and 94.5%, respectively. Multivariate analysis indicated that pT [pT2 vs. pT1, hazard ratio (HR) of 2.63], tumor thickness [≥5mm vs.


CK4 is a novel predictive marker for recurrence in early TSCC. The combination of CK4 with clinicopathlogical factors predicted recurrence and cancer specific death in this population.

Clinical trial identification

Legal entity responsible for the study

National cancer center




All authors have declared no conflicts of interest.